LEXINGTON, Mass. and AMSTERDAM, The Netherlands, May 07, 2018 (GLOBE NEWSWIRE) -- uniQure N.V.(Nasdaq:QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs, such as hemophilia B, Huntington’s disease and congestive heart failure, today announced the closing of its previously announced underwritten public offering of 5,175,000 of its ordinary shares at a public offering price of $28.50 per share, which includes the full exercise of the underwriters' option to purchase 675,000 additional shares. The gross proceeds to uniQure from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by uniQure, are $147,487,500. All ordinary shares sold in the offering were sold by uniQure.

Leerink Partners, Evercore ISI and Wells Fargo Securities acted as joint book-running managers for the offering. Chardan and H.C. Wainwright & Co. acted as co-lead managers, and Janney Montgomery Scott acted as co-manager for the offering.

About uniQure 

uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. We are leveraging our modular and validated gene therapy technology platform to advance a pipeline of proprietary and partnered gene therapies to treat patients with hemophilia, Huntington’s disease and cardiovascular diseases.